发明名称 SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
摘要 <p>The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.</p>
申请公布号 WO2010023866(A1) 申请公布日期 2010.03.04
申请号 WO2009JP04059 申请日期 2009.08.24
申请人 ONCOTHERAPY SCIENCE, INC.;NAKAMURA, YUSUKE;DAIGO, YATARO;TOGASHI, AKIRA 发明人 NAKAMURA, YUSUKE;DAIGO, YATARO;TOGASHI, AKIRA
分类号 C12N15/09;A61K31/713;A61K48/00;A61P35/00;C12Q1/68;G01N33/15;G01N33/53 主分类号 C12N15/09
代理机构 代理人
主权项
地址